Special Issue "Aporphines and Oxoaporphines"

Quicklinks

A special issue of Molecules (ISSN 1420-3049).

Deadline for manuscript submissions: closed (30 June 2009)

Special Issue Editor

Guest Editor
Dr. Eduardo Sobarzo-Sánchez
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, E-15782 Santiago de Compostela, Spain
Website: http://www.usc.es
E-Mail:
Interests: medicinal chemistry; natural products; photochemistry reactivity; aporphine and oxoaporphine; oxoisoaporphine; coumarins

Published Papers

Special Issue Information

Submission

All papers should be submitted to molecules@mdpi.org with copy to the guest editor. To be published continuously until the deadline and papers will be listed together at the special websites.
Submitted papers should not have been previously published nor be currently under consideration for publication elsewhere. All papers are refereed through a peer review process. A guide for authors, sample copies and other relevant information for submitting papers are available on the Instructions for Authors page. Molecules is an international peer-reviewed monthly journal published by Molecular Diversity Preservation International.
Please visit the Instructions for Authors page before submitting a paper. Open Access publication fees are 800 CHF per paper. English correction fees (250 CHF) will be added in certain cases (1050 CHF per paper for those papers that require extensive additional formatting and/or English corrections.).

Keywords

medicinal chemistry, natural products, photochemistry reactivity, aporphine and oxoaporphine, oxoisoaporphine, coumarins

Planned Papers

Manuscript ID: molecules-aporph-20080915-tw-Chen
Type of Paper: Article
Tentative Title: Liriodenine Compound Inhibits in vitro Dengue Virus Replication or Anti-dengue Viral Activity of Liriodenine Derivatives
Authors: Chung-Yi Chen
Affiliation: School of Medicine and Health Sciences, Fooyin University, Kaohsiung Hsien 831, Taiwan
E-mail: xx377@mail.fy.edu.tw
Abstract: Dengue viruses (DV) are mosquito-borne flaviviruses that cause a large number of human infections worldwide each year. No vaccines or chemotherapeutics are currently available. Therefore, the increasing number of outbreaks of dengue hemorrhagic fever caused by DV infection brings out an urgent need to develop potent anti-DV agents. A collection of hundreds of pure components isolated from the native plants of Taiwan, we found purified compounds of Michelia alba for the activities to suppress DV replication using a stable subgenomic dengue virus replicon system that expressed firefly luciferase reporter and neomycin phosphotransferase (Neo) genes in BHK21 cell lines. The results indicated that the liriodenine (aporphime) compound can significantly reduce luciferase-reporter activity in a dose dependent manner. The 50% effective concentration (EC50) was 22.0 ± 2.0 μM and no mitrochondrial toxicity was observed at this effective concentration. Furthermore, the liriodenine compound exhibited a synergistic antiviral activity in combination with IFN-α in DV replicon system, in which the antiviral response was better than IFN-α alone. Collectively, these data suggested that this novel inhibitor could be developed for potential treatment of DV infection through combination with other therapeutics.

Last update: 12 February 2009

Molecules EISSN 1420-3049 Published by MDPI Publishing, Basel, Switzerland RSS E-Mail Table of Contents Alert